CommercialCoverageMedium impact
06.02.53, Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Independence Blue Cross·Urology, Oncology·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Policy 06.02.53 regarding protein biomarkers for prostate cancer diagnosis and risk assessment was reissued effective October 1, 2025. Without access to the full policy content, the specific coverage criteria, billing code requirements, and prior authorization mandates cannot be determined. The billing team must obtain and review the complete policy document to understand what changed from the previous version and identify any new compliance requirements.
Action Required
By October 1, 2025: Billing team must obtain the complete policy text from the provided URL (https://medpolicy.ibx.com/ibc/Commercial/Pages/Site-Activity-View.aspx?FilterField1=MPSiteActivityLogMonth&FilterValue1=10&FilterField2=MPSiteActivityLogYear&FilterValue2=2025#commercial-06-02-53). Review the full reissued policy to identify: (1) specific CPT/HCPCS codes affected, (2) prior authorization requirements, (3) coverage limitations, and (4) documentation requirements. Update billing system, encounter forms, and provider communications accordingly. Flag any differences from the previous version of 06.02.53 and communicate changes to urology and oncology providers. Failure to implement required prior authorization may result in claim denials.